Top Markets
#1 QuantixAI QuantixAI +34.75%
#2 Siren Siren +30.13%
#3 MowCat MowCat +27.45%
#4 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +24.55%
#5 Prom Prom +23.43%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +18.49%
#7 UnifAI Network UnifAI Network +18.36%
#8 Versatize Coin Versatize Coin +16.67%
#9 Pons Pons +15.01%
#10 Tutorial Tutorial +14.17%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Bioceltix S.a. Bioceltix S.a.

Bioceltix S.a.

BCX
Rank in Stocks #20676
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals... Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Share Price
$22.52
Last synced: 2026-08-21
Market Cap
$124.60M
Change (1 day)
-1.11%
Change (1 year)
-21.94%
Country
PL
Trade Bioceltix S.a. (BCX)

Category

Healthcare
P/E ratio for Bioceltix S.a. (BCX)
P/E ratio as of 2026 TTM: 0
According to Bioceltix S.a. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Bioceltix S.a. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.